The future of blood-based biomarkers in liver cancer.

Blood-based biomarkers show promise for liver cancer but require further validation before widespread clinical use.

• Why it matters: Effective biomarkers are crucial for improving risk assessment, early detection, and treatment monitoring in liver cancer, yet current validation efforts are limited.
• What they did: The review summarizes existing blood-based biomarkers across the liver cancer care continuum and highlights the need for rigorous evaluation through clinical trials and cohort studies.
• The result: Advancing validation efforts may enable these biomarkers to enhance personalized management and early diagnosis of hepatocellular carcinoma and biliary tract cancers.